Check out the most recent publications featuring the GA-Map Dysbiosis Test Lx! These studies used the GA-Map Dysbiosis Test Lx to help determine how the gut microbiota takes part in various diseases such as IBS and axial spondyloarthritis. Find them below:
Principle of Analysis
The GA-map® Dysbiosis Test Lx v2 is a test that maps the intestinal microbiota profile for a selected set of bacteria. The GA-map® platform uses probes that target variable regions (V3 to V7) of the bacterial 16S rRNA gene to characterize and identify bacteria present. The targets are identified in a molecular multiplex assay that utilizes the Single Nucleotide Primer Extension (SNuPE) technology patented by Professor Knut Rudi (US6617138). A unique algorithm takes advantage of all the data generated by the detection of the SnuPE products to determine dysbiosis level in the sample. The algorithm is incorporated in the GA-map® Dysbiosis Analyzer software that accompanies the test.